Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem.86.8.7750 ◽

2001 ◽

Vol 86 (8) ◽

pp. 3717-3723 ◽

Author(s):

Mai-Britt Toft-Nielsen ◽

Mette B. Damholt ◽

Sten Madsbad ◽

Linda M. Hilsted ◽

Thomas E. Hughes ◽

...

Keyword(s):

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

The association of the fasting serum level of glucagon like peptide-1 (GLP-1) with oxidative stress, atherosclerotic vascular changes and cardiometabolic risk factors in type 2 diabetic patients

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.06.399 ◽

2018 ◽

Vol 275 ◽

pp. e136

Author(s):

T. Abdel Aaty ◽

M. Rezk ◽

E. Morsy ◽

K. Moghazy ◽

N. Amin ◽

...

Keyword(s):

Oxidative Stress ◽

Cardiometabolic Risk ◽

Diabetic Patients ◽

Vascular Changes ◽

Fasting Serum ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz et al.

Diabetes Care ◽

10.2337/diacare.27.11.2771 ◽

2004 ◽

Vol 27 (11) ◽

pp. 2771-2771

Author(s):

T. Damci ◽

S. Yalin ◽

H. Balci ◽

Z. Osar ◽

U. Korugan ◽

...

Keyword(s):

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients

Journal of Endocrinological Investigation ◽

10.1007/s40618-014-0161-y ◽

2014 ◽

Vol 38 (2) ◽

pp. 143-147 ◽

Author(s):

D. A. de Luis ◽

R. Aller ◽

O. Izaola ◽

R. Bachiller

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Diabetic Patients ◽

Gene Variant ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment

Diabetes Care ◽

10.2337/diacare.24.8.1416 ◽

2001 ◽

Vol 24 (8) ◽

pp. 1416-1421 ◽

Author(s):

J. Larsen ◽

B. Hylleberg ◽

K. Ng ◽

P. Damsbo

Keyword(s):

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Sulphonylurea Treatment ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in Type 2 diabetic patients

Diabetic Medicine ◽

10.1002/(sici)1096-9136(199806)15:6<485::aid-dia610>3.0.co;2-y ◽

1998 ◽

Vol 15 (6) ◽

pp. 485-491 ◽

Author(s):

C. Seifarth ◽

J. Bergmann ◽

J.J. Holst ◽

R. Ritzel ◽

W. Schmiegel ◽

...

Keyword(s):

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Enhanced Secretion ◽

Glucagon Like Peptide ◽

Oral Sucrose ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

SP474TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE DECREASES ALBUMINURIA IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfv195.18 ◽

2015 ◽

Vol 30 (suppl_3) ◽

pp. iii536-iii536

Author(s):

Tomislav Bulum ◽

Kristina Blaslov ◽

Ingrid Prkačin ◽

Karin Zibar ◽

Lea Duvnjak

Keyword(s):

Receptor Agonist ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients

Diabetic Medicine ◽

10.1111/j.1464-5491.2005.01451.x ◽

2005 ◽

Vol 22 (4) ◽

pp. 470-476 ◽

Author(s):

K. Hücking ◽

Z. Kostic ◽

C. Pox ◽

R. Ritzel ◽

J. J. Holst ◽

...

Keyword(s):

Gastric Emptying ◽

Delay Gastric Emptying ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure

Diabetes Care ◽

10.2337/diacare.21.11.1925 ◽

1998 ◽

Vol 21 (11) ◽

pp. 1925-1931 ◽

Author(s):

M. A. Nauck ◽

A. Sauerwald ◽

R. Ritzel ◽

J. J. Holst ◽

W. Schmiegel

Keyword(s):

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Fasting Glycemia ◽

Secondary Failure ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

Cardiovascular Diabetology ◽

10.1186/1475-2840-12-73 ◽

2013 ◽

Vol 12 (1) ◽

pp. 73 ◽

Author(s):

Miao-yan Zheng ◽

Ju-hong Yang ◽

Chun-yan Shan ◽

Hong-tao Zhou ◽

Yan-guang Xu ◽

...

Keyword(s):

Preliminary Report ◽

Diabetic Patients ◽

Newly Diagnosed ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text

Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?

Current Clinical Pharmacology ◽

10.2174/157488471403191231143537 ◽

2019 ◽

Vol 14 (3) ◽

pp. 247-248

Author(s):

Thekkuttuparambil A. Ajith

Keyword(s):

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Type 2 Diabetic

Download Full-text